ACS Pharmacol Transl Sci首个影响因子达到6，JCI达到1.61
作为美国化学学会的ACS系列期刊之一，ACS Pharmacol在2023年获得首个影响因子，IF 6。期刊引用指示JCI 1.61。
这在药理学和药学领域均属于Q1。
ACS Pharmacol虽然与Br J Pharmacol的IF 7.3、中国药理学报Acta Pharmacol Sin的IF 8.2、Pharmacol Res的9.3
还有差距，但是刚刚超过了著名传统老刊Biochem Pharmacol的5.8。
ACS Pharmacol的首个IF能够达到6，反映了药理学研究领域的强劲势头。
欢迎浏览我们2022年在ACS Pharmacol Transl Sci发表的，关于光动力激活CCK1受体机制的论文：
Transmembrane Domain 3 Is a Transplantable Pharmacophore in the Photodynamic Activation of Cholecystokinin 1 Receptor
跨膜序列3是光动力激活CCK1受体的可移植药效学部位(ACS Pharmacol. Transl. Sci.5: 539–547, 2022)，链接如下：
Transmembrane Domain 3 Is a Transplantable Pharmacophore in the Photodynamic Activation of Cholecystokinin 1 Receptor | ACS Pharmacology & Translational Science
Abstract
Cholecystokinin 1 receptor (CCK1R) is activated in photodynamic action by singlet oxygen, but detailed molecular mechanisms are not elucidated. To identify the pharmacophore(s) in photodynamic CCK1R activation, we examined photodynamic activation of point mutants CCK1RM121/3.32A, CCK1RM121/3.32Q, and a chimeric receptor with CCK1R transmembrane domain 3 (TM3) transplanted to muscarinic ACh receptor 3 (M3R) which is unaffected by photodynamic action. These engineered receptors were tagged at the N-terminus with genetically encoded protein photosensitizer miniSOG, and their light-driven photodynamic activation was compared to wild type CCK1R and M3R, as monitored by Fura-2 fluorescent calcium imaging. Photodynamic activations of miniSOG-CCK1RM121/3.32A and miniSOG-CCK1RM121/3.32Q were found to be 55% and 73%, respectively, when compared to miniSOG-CCK1R (100%), whereas miniSOG-M3R was not affected (0% activation). Notably, the chimeric receptor miniSOG-M3R-TM3CCK1R was effectively activated photodynamically (65%). These data suggest that TM3 is an important pharmacophore in photodynamic CCK1R activation, readily transplantable to nonsusceptible M3R for photodynamic activation.
KEYWORDS:
转载本文请联系原作者获取授权，同时请注明本文来自崔宗杰科学网博客。
链接地址：https://wap.sciencenet.cn/blog-39029-1394263.html?mobile=1
收藏
